GLP1R and thyroid gland carcinoma: After PSM (Figure 2), The increased incidence risks of acute nephritis (sHR: 1.62, 95% CI: 1.15–2.28), thyroid cancer (sHR: 1.61, 95% CI: 1.01–3.01), and skin follicular cysts (sHR: 2.03, 95% CI: 1.24–3.30) were observed when using GLP‐1 RAs under 12 months; For over 12 months of GLP‐1 RAs usage group, significantly increased incidence risks of acute nephritis (sHR: 2.24, 95% CI: 1.24–4.03), thyroid dysfunction (sHR: 1.57, 95% CI: 1.03–2.40), and acne (sHR: 4.29, 95% CI: 1.57–11.75) were also observed.